Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +91.67%. A quarter ago, it was expected that this company would post a loss of $0.33 per share when it actually produced a loss of $0.28, delivering a surprise of +15.15%.Over the last four quarters, the company ha ...

Daré Bioscience (NasdaqCM:DARE) Q4 2025 Earnings call March 26, 2026 04:30 PM ET Company ParticipantsDouglas Tsao - Managing Director of Equity ResearchLeona Nease - Biotech Equity Research AssociateMarDee Haring-Layton - Chief Accounting OfficerSabrina Martucci Johnson - President and CEOConference Call ParticipantsKemp Dolliver - Director of Research and Senior AnalystOperatorWelcome to the conference call hosted by Daré Bioscience to review the company's 2025 financial results and provide a business upda ...

Daré Bioscience (NasdaqCM:DARE) Q4 2025 Earnings call March 26, 2026 04:30 PM ET Company ParticipantsDouglas Tsao - Managing Director of Equity ResearchLeona Nease - Biotech Equity Research AssociateMarDee Haring-Layton - Chief Accounting OfficerSabrina Martucci Johnson - President and CEOConference Call ParticipantsKemp Dolliver - Director of Research and Senior AnalystOperatorWelcome to the conference call hosted by Daré Bioscience to review the company's 2025 financial results and provide a business upda ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________ FORM 10-K ___________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____ TO_____ Commission File No. 001-36395 DARÉ BIOSCIENCE, INC. (Exa ...

FOR IMMEDIATE RELEASE March 26, 2026 DARÉ BIOSCIENCE, INC. Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, CA, March 26, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in ...

Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today reported financial results for the year ended December 31, 2025, and provid ...

DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For HerSAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Every year on March 27th, National Viagra Day celebrates a drug that transformed sexual health for millions of men. Today, Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, is declaring that the conversation is long overdue for an upgrade — and that the ...

SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 26, 2026, to review its financial results for the year ended December 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (t ...

• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026• DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options• Award reflects Daré's strategy of leveraging non-dilutive grant funding to advance a deep, differentiated pipeline addressing the most persistent unmet needs in women's health SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused o ...